摘要
目的研究奥司他韦联合注射用重组人干扰素α1b治疗小儿流感病毒肺炎的效果。方法在2019年8月—2020年8月本院接诊的流感病毒肺炎患儿中选取108例,随机数字法均分为对照组(单纯重组人干扰素alpha1b治疗)、研究组(重组人干扰素alpha1b、奥司他韦联合治疗),记录比较患儿的治疗状况、治疗有效率及用药不良反应状况。结果对照组用药时间、肺部啰音消失时间、退热时间以及住院时间分别是(8.36±0.75)、(11.03±2.01)、(3.17±0.77)、(13.23±1.65)d,研究组用药时间、肺部啰音消失时间、退热时间以及住院时间分别是(7.11±0.64)、(7.69±1.24)、(1.54±0.46)、(8.71±1.22)d,研究组用药时间、肺部啰音消失时间、退热时间以及住院时间均明显比对照组早/短(P<0.05)。对照组的治疗效果为66.7%,研究组的治疗效果为83.3%,研究组治疗效果比对照组更佳(χ^(2)=4.00,P<0.05)。对照组不良反应总发生率为24.1%,研究组不良反应总发生率为9.3%,研究组用药不良反应状况的发生率比对照组低(χ^(2)=4.27,P<0.05)。对照组患儿用药成本、住院成本、总成本分别为(2411.6±256.9)、(4023.6±455.9)、(6912.3±640.9)元,研究组患儿用药成本、住院成本、总成本分别为(2113.9±214.9)、(3756.3±401.1)、(6011.9±598.7)元,研究组患儿用药成本、住院成本、总成本均比对照组低(t=6.53、3.23、7.54,P<0.05)。结论在治疗流感病毒肺炎患儿时,注射用重组人干扰素α1b、奥司他韦联合,可以改善整体治疗状况,提高治疗效果,减少用药不良症状的发生,不仅安全性更高,且更加经济。
Objective To study the effect of oseltamivir combined with recombinant human interferonα1b in the treatment of infantile influenza virus pneumonia.Methods Randomly selected 108 children with influenza virus pneumonia admitted to our hospital from August 2019 to August 2020,and randomly divided them into the control group(recombinant human interferonα1b treatment)and the study group(recombinant human interferonα1b and oseltamivir combined therapy),record and compared the children's treatment status,treatment efficiency and adverse drug reaction status.Results The study group's medication time,lung rale disappearance time,antipyretic time,and hospital stay were(8.36±0.75),(11.03±2.01),(3.17±0.77),(13.23±1.65)d,and the control group were(7.11±0.64),(7.69±1.24),(1.54±0.46),(8.71±1.22)d,respectively.The study group's medication time,lung rales disappearance time,antipyretic time and hospital stay were significantly earlier/shorter than those in the control group(P<0.05).The treatment effect of the control group was 66.7%,the treatment effect of the study group was 83.3%,and the treatment effect of the study group was better than that of the control group(χ^(2)=4.00,P<0.05).The total incidence of adverse reactions in the control group was 24.1%,and the total incidence of adverse reactions in the study group was 9.3%.The incidence of adverse reactions in the study group was lower than that in the control group(χ^(2)=4.27,P<0.05).The medication cost,hospitalization cost,and total cost of children in the control group were(2411.6±256.9),(4023.6±455.9)yuan,and(6912.3±640.9)yuan,respectively.The drug cost,hospitalization cost,and total cost of the study group were(2113.9±214.9),(3756.3±401.1)yuan,and(6011.9±598.7)yuan.The cost of medication,hospitalization and total cost of children in the study group were lower than those in the control group(t=6.53,3.23,7.54,P<0.05).Conclusion In The treatment of children with influenza virus pneumonia,the combination of recombinant humanα1b and oseltamivir can improve the overall treatment status,improve the treatment effect,and reduce the occurrence of adverse symptoms of medication.It is not only safer,but also more economical.
作者
吴锦荣
WU Jinrong(Department of Pediatrics,The 900th Hospital of the JointLogistics Support Force of the Chinese People's Liberation Army,Fuzhou Fujian 350025,China)
出处
《中国卫生标准管理》
2022年第4期109-113,共5页
China Health Standard Management
关键词
奥司他韦
注射用重组人干扰素α1b
小儿
流感病毒
肺炎
疗效
oseltamivir
recombinant human interferonα1b for injection
children
influenza viru
pneumonia
curative effect
